Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 5, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 35,393 Ordinary Shares from the GlaxoSmithKline Employee Trust ("GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 2, 2005, and was advised to the company on September 5, 2005.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust for current and former employees, with three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) holding interests in the trust shares similarly to other employees.
Key Facts for Investor Verification
- Transaction Date: September 2, 2005.
- Shares Transferred: 35,393 Ordinary Shares.
- Source: GlaxoSmithKline Employee Trust (GSK Trust).
- Beneficiaries: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Directors Involved: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop have interests in the trust shares.